Bedford, Nova Scotia–(Newsfile Corp. – July 22, 2019) – Roscan Gold Corporation (TSXV: ROS) (“Roscan” or the “Company”) is pleased to announce the positive assay results from both its diamond drilling and air core (AC) drilling programs at its Kandiole Project in Mali, West Africa. This drilling program was completed during April to July of 2019 and was designed to test both the north and south extensions of the Mankouke gold discovery zone and many other strong termite and soil, gold anomalies.
The Mankouke gold discovery has been shown, by detailed drilling, to have a strike length of at least 500 metres. In addition, the recent very impressive AC drilling assay results at the southern end of the Mankouke permit, as shown in Figure 1, supports the existence of a 7-kilometer long mineralization target corridor associated with the Mankouke discovery.
|In hole ACMan 19-167||5.86 g/t Au over 26.0 m (incl. 9.44 g/t Au over 10.0 m)|
|In hole ACMan 19-168||3.74 g/t Au over 30.0 m (incl. 6.73 g/t Au over 6.0 m)|
|In hole DDH 19-04||8.63 g/t Au over 10.0 m (incl. 11.48 g/t Au over 7.0 m)|
|In hole DDH 19-03||6.53 g/t Au over 5.0 m (incl. 10.09 g/t Au over 3.0 m)|
|In hole DDH 19-03||5.56 g/t Au over 3.0 m (incl. 7.14 g/t Au over 2.0 m)|
|In hole DDH 19-08||3.45 g/t Au over 10.0 m (incl. 6.76 g/t Au over 3.0 m)|
Note: True widths cannot be determined with the information available
A summary of all assay results is presented in Table 1.
Greg Isenor, President and CEO of Roscan Gold, stated: “We are continuing to show that we have an excellent new gold discovery at Mankouke that appears to have strike and depth continuity. Our land package has great potential and we are extremely encouraged by the hits we are seeing on the Mankouke permit. There are many assays yet to be received and these will be available in the coming weeks. We are extremely pleased our approach to exploration in this area has been successful. Additional drilling is part of an obvious next step.
The drilling around the Mankouke discovery shows that a strong mineralization system exists and is” alive”. This is not supergene mineralization. We have drilled 19 core holes and have received results for 11 and have significant assays in 8 of the 11 holes. We are waiting for results for both AC and DDH on the north extension of the trend. (See fig 2). Deeper holes are planned when we return to drilling after the rain season. The drilling season is over for a few months, however many results yet to be received. We have the funds to continue drilling after the seasonal rains (July to October). In addition, the excellent AC results we received in the south of the Mankouke permit (see fig 1) will be followed up as soon as possible.“
The drilling was carried out during the period May to July with two rigs, one air core drilling rig and one multi-purpose diamond drilling rig. The diamond drilling was completed in the Mankouke discovery zone area and designed to test for extensions to the zone. The drilling program has been suspended until the end of the rainy season. At this point in the drilling program, there has been 19 diamond drill holes completed for a total of 2,017 meters. Assay results have not been received for eight diamond drill holes. See Figure 2.
A total of 607 AC holes were drilled for a total meterage of 28,037 metres. Approximately 60% of the assays of the AC drilling have been received. The AC drilling covered the entire land package with testing the most important termite anomalies. Lines of AC holes were drilled across the target areas generally in an east-west direction and drilled at -50 degrees to the west to a depth of 45 to 60 metres in a heel to toe fashion. AC drilling is used to sample unconsolidated ground with compressed air used to remove the cuttings from the hole. During the Kandiole drilling program, 2 metres long samples were collected. For each 2 metre intersection an ~2-kilogram sample was collected and sent to the laboratory. A check sample of approximately 5 kilograms was collected for possible future tests.
The gold mineralization intersected to date in the Mankouke Zone is hosted in breccia zones which are interbedded with saprolitic metasediments. Recent core holes have intersected gold mineralized breccia (8.63 g/t Au over 10 metres from 79.1 metres to 89.1 metres along the drill hole) at a vertical depth of 60 metres. This drilling indicates that the initially reported gold discovery (News Release January 24, 2019) has “roots” and is not near surface enrichment (supergene). This drilling information clearly shows the potential at depth in this area and identifies that this is typical Birimian, hydrothermal-type gold mineralization.
Additional interpretation will be completed when all data is available.
Remaining assays will be received and processed during the rainy season. It is expected that drilling will resume as early as mid-October and will primarily consist of both diamond drilling, to test for both the extensions of the Mankouke gold discovery, and, to test significant AC intersections identified in other areas of the property. In addition, AC drilling will be continued to test the remaining, untested termite and gold soil anomalies.
QUALIFIED PERSON AND SAMPLE PROTOCOL
The technical content in this news release has been reviewed and approved by Gregory P. Isenor, P. Geo, a Qualified Person as defined by NI 43-101.
For quality control, duplicated samples were systematically collected in the field, and blank samples were inserted in the sample batches sent to the laboratory. Before their transportation, the samples were stored in a Roscan secured location in the field. Batches of samples were transported by truck, driven by Roscan contractors, to the Bureau Veritas laboratory sample preparation installation of in Bamako; prepared samples were then shipped by Bureau Veritas to their treatment installation at Abidjan, Ivory Coast. During the assay process, the laboratory applied its own quality controls with blanks, duplicates and standard samples. The assay method was atomic absorption (AA) with pre-concentration by fire assay (FA); the detection limit of the method is of 5 ppb.
Roscan Gold Corporation is a Canadian gold exploration company focused on the acquisition and exploration of gold properties in West Africa. The Company has assembled a significant land position of 100%-owned permits in an area of producing gold mines (including B2 Gold’s Fekola Mine which lies in a contiguous property to the west of Kandiole), and major gold deposits, located both north and south of its Kandiole Project in west Mali.
For further information, please contact:
President and Chief Executive Officer
Tel: (902) 832-5555
Forward Looking Statements
This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information is characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, and opportunities to differ materially from those expressed or implied by such forward-looking information. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, changes in the state of equity and debt markets, fluctuations in commodity prices, delays in obtaining required regulatory or governmental approvals, and other risks involved in the mineral exploration and development industry, including those risks set out in the Company’s management’s discussion and analysis as filed under the Company’s profile at www.sedar.com. Forward-looking information in this news release is based on the opinions and assumptions of management considered reasonable as of the date hereof, including that all necessary governmental and regulatory approvals will be received as and when expected. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information. The Company disclaims any intention or obligation to update or revise any forward-looking information, other than as required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SIGNIFICANT ASSAY RESULTS
AIR CORE DRILLING PROGAM 2019
|Hole #||Line #||FROM|
|ACKaN-19-06||S 1383715 N||2.0|
|0.68 g/t Au over 2.0 m|
1.05 g/t Au over 2.0 m
0.71 g/t Au over 2.0 m
0.72 g/t Au over 2.0 m
|ACMan-19-47||S 1379900 N||30.0||32.0||0.56 g/t Au over 2.0 m|
|ACMan-19-48||S 1379900 N||12.0||14.0||0.62 g/t Au over 2.0 m|
|ACMan-19-49||S 1379900 N||16.0||22.0||0.49 g/t Au over 6.0 m|
|ACMan-19-51||S 1379900 N||2.0|
|1.92 g/t Au over 2.0 m|
1.46 g/t Au over 6.0 m
1.34 g/t Au over 2.0 m
|ACMan-19-74||S 1382160 N||34.0||36.0||0.51 g/t Au over 2.0 m|
|ACMan-19-84||S 1380600 N||30.0|
|1.24 g/t Au over 10.0 m|
0.53 g/t Au over 2.0 m
|ACMan-19-85||S 1380600 N||38.0||44.0||2.44 g/t Au over 6.0 m|
|ACMan-19-86||S 1380600 N||12.0|
|3.10 g/t Au over 2.0 m|
4.29 g/t Au over 4.0 m
|ACMan-19-88||S 1380650 N||14.0||16.0||3.75 g/t Au over 2.0 m|
|ACMan-19-89||S 1380650 N||42.0||44.0||0.79 g/t Au over 2.0 m|
|ACMan-19-90||S 1380650 N||16.0||18.0||2.18 g/t Au over 2.0 m|
|ACMan-19-155||S 1382350 N||18.0||20.0||2.15 g/t Au over 2.0 m|
|ACMan-19-163||S 1375850 N||36.0||42.0||1.24 g/t Au over 6.0 m|
|ACMan-19-165||S 1375850 N||6.0|
|0.91 g/t Au over 4.0 m|
2.37 g/t Au over 2.0 m
|ACMan-19-166||S 1375850 N||6.0|
|1.40 g/t Au over 18.0 m|
8.14 g/t Au over 4.0 m
6.13 g/t Au over 6.0 m
|ACMan-19-167||S 1375850 N||4.0|
|4.50 g/t Au over 16.0 m|
Inc. 23.00 g/t Au over 2.0 m
5.86 g/t Au over 26.0 m
Inc. 10.20 g/t Au over 2.0 m
Inc. 9.44 g/t Au over 10.0 m
|ACMan-19-168||S 1375850 N||4.0|
|3.00 g/t Au over 10.0 m|
Inc. 10.60 g/t Au over 2.0 m
3.74 g/t Au over 30.0 m
Inc. 6.73 g/t Au over 6.0 m
Inc. 9.19 g/t Au over 4.0 m
|ACMan-19-169||S 1375850 N||0.0|
|0.54 g/t Au over 2.0 m|
1.34 g/t Au over 8.0 m
3.23 g/t Au over 12.0 m
Inc. 5.92 g/t Au over 4.0 m
|ACMan-19-170||S 1375850 N||10.0|
|2.76 g/t Au over 26.0 m|
Inc. 6.76 g/t Au over 2.0 m
Inc. 8.74 g/t Au over 4.0 m
|ACMan-19-171||S 1375850 N||6.0||8.0||0.64 g/t Au over 2.0 m|
|ACMan-19-181||S 1377200 N||4.0||6.0||1.31 g/t Au over 2.0 m|
|ACMan-19-189||S 1377200 N||26.0||28.0||1.01 g/t Au over 2.0 m|
|ACMan-19-196||S 1377200 N||4.0||6.0||1.59 g/t Au over 2.0 m|
|ACMan-19-200||S 1377420 N||22.0||24.0||2.10 g/t Au over 2.0 m|
|ACMan-19-217||S 1377420 N||6.0|
|1.00 g/t Au over 6.0 m|
0.99 g/t Au over 2.0 m
|ACMan-19-229||S 1378200 N||24.0||26.0||0.65 g/t Au over 2.0 m|
|ACMou-19-01||S 1398350 N||0.0||2.0||1.33 g/t Au over 2.0 m|
|ACMou-19-03||S 1398350 N||12.0|
|0.81 g/t Au over 4.0 m|
0.54 g/t Au over 2.0 m
|ACMou-19-08||S 1398080 N||26.0||28.0||0.79 g/t Au over 2.0 m|
|ACMou-19-10||S 1397290 N||6.0|
|0.52 g/t Au over 2.0 m|
3.82 g/t Au over 6.0 m
Inc. 8.46 g/t Au over 2.0 m
|ACNia-19-04||S 1380260 N||20.0||22.0||0.64 g/t Au over 2.0 m|
Note 1: This table includes all the mineralized intersections with a grade > 0.50 g/t Au; these intersections are considered as significant intersections.
Note 2: Intersections in bold refer to intersections with a grade > 0.50 g/t Au, and a length > 2.0.
Note 3: True widths cannot be determined with the information available.
DIAMOND DRILLING PROGRAM 2019
|Hole #||Line #||FROM|
|1.04 g/t Au over 4.0 m|
1.97 g/t Au over 1.0 m
|DDHMan-19-02||1380500 N||75.1||77.1||0.99 g/t Au over 2.0 m|
|5.56 g/t Au over 3.0 m|
Inc. 7.14 g/t Au over 2.0 m
6.48 g/t Au over 2.0 m
Inc. 8.98 g/t Au over 1.0 m
6.53 g/t Au over 5.0 m
Inc. 10.09 g/t Au over 3.0 m
2.60 g/t Au over 0.9 m
|1.69 g/t Au over 1.0 m|
0.80 g/t Au over 4.0 m
8.63 g/t Au over 10.0 m
Inc. 11.48 g/t Au over 7.0 m
|1.30 g/t Au over 1.0 m|
0.73 g/t Au over 1.0 m
|0.71 g/t Au over 1.0 m|
14.88 g/t Au over 1.6 m
Inc. 34.00 g/t Au over 0.6 m
0.58 g/t Au over 1.0 m
|1.07 g/t Au over 1.0 m|
12.70 g/t Au over 1.0 m
3.45 g/t Au over 10.0 m
Inc. 6.76 g/t Au over 3.0 m
6.29 g/t Au over 1.0 m
|DDHMan-19-12||1380600 N||104.0||105.0||1.07 g/t Au over 1.0 m|
|0.75 g/t Au over 1.0 m|
1.10 g/t Au over 1.0 m
0.64 g/t Au over 1.0 m
4.16 g/t Au over 2.0 m
Inc. 7.81 g/t Au over 1.0 m
0.56 g/t Au over 1.0 m
1.51 g/t Au over 1.0 m
Note 1: This table includes all the mineralized intersections with a grade > 0.50 g/t Au; these intersections are considered as significant intersections.
Note 2: Intersections in bold refer to intersections with a grade > 0.50 g/t Au, and a length > 2.0.
Note 3: True widths cannot be determined with the information available.Cannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/ea5917b2bb71d8cd5cb3d04eb3e0b297More
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/4821/46368_b01c8377e4b94ae8_001full.jpgCannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/35ccfc69eef57cdc1b5b20a061166663More
To view an enhanced version of Figure 2, please visit:
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/46368
Advanced Micro Devices (AMD)’s FALL IN REVENUE JUST A HITCH
Advanced Micro Devices, Inc. (NASDAQ: AMD) reported a slump in its revenue in Q2. Management also alerted of the company’s top-line growth to be in mid-single-digit for the year. AMD stock was quick to be sold at the signs of distress amidst other chip stocks. But, this distress is not something that would last long and is just a short-term hitch.
Can AMD Stock Price Come Back Stronger?
The revenue decline was over 13% annually and operating margins have shriveled by 4%. This bust can be credited to the inventory of graphics card channel that stood oversupplied due to the failure of crypto-currency. The company’s expected revenue for Q3 is $1.8 billion at the mid-point of its guidance range. Even though this figure is an increase (9%) as compared to the previous year’s figure, it fails to live up to Wall Street’s expectation of $1.94 billion.
The sagging to-line growth is due to the slow demand of the company’s semi-custom chips, as claimed by AMD’s CFO Devinder Kumar. Due to the upcoming launch of next-generation hardware next year by both Sony and Microsoft, the demand for gaming consoles has gone down currently as more and more game enthusiasts are holding off buying the gaming console.
This has largely affected AMD stock price due to the simple reason that the semi-custom chips that the company manufactures are actually used by Sony and Microsoft for their gaming consoles. Due to the fall in current demand, Sony announced a cut in its fiscal 2020’s sale forecast for PlayStation 4, thereby reducing the order of the semi-custom chips. However, with the launch of next-generation gaming hardware, business for AMD is likely to rapidly pace up again.
Moreover, the company is also making successful strides in its other segments like the Ryzen processors becoming a catalyst for AMD in the CPU space. The launch of AMD’s latest 7-nanometer Ryzen CPUs with their superior performance and lower power consumption would likely gain more market share for the company. Rome, AMD’s new server processor, has also started being shipped and would make its space in the server market. Also, the revenue from AMD’s GPU has also increased in double-digit percentage.
Keeping all these in mind, the slump in Q2’s revenue of the company does seem like a minor bump in the bright road of the company’s future.
Multi-Billion Dollar Markets Are Ready For A Shake-Up; 1 Biotech Stock Could Hold The Key
One Small Biotech Stock Could Hold Humira’s Kryptonite
There’s no denying that biotechnology is one of the hottest markets in the world. Right now a multi-billion-dollar segment is ready for a shakeup and one biotech stock could hold the secret to doing just that!
More times than not, biotechnology and healthcare stocks are the “hot markets” and we’ll explain exactly why. We’ll also take a deep dive into a niche that you must be paying attention to in 2019 if you’re looking to take advantage of the next big trend in health science.
Why biotech over other sectors? With this sector we’re literally talking about companies creating life-changing and life-saving treatments. And in the process, some of the greatest wealth has been created. Merck is acquiring cancer drug developer Peloton Therapeutics for $1.05 billion. Pharmaceutical giant Bristol-Myers, a pioneer in immunotherapy, is acquiring rival Celgene for $74 billion.
The announcement came as Peloton was preparing for its IPO. Earlier this year, Eli Lilly bought Loxo Oncology for $8 billion. And these are just a few of the many BIG stories that biotech investors are witnessing first hand!
Biotech stocks have delivered sizzling returns over the last few years. New drugs have improved the lives of patients and made big profits for investors in the process. Creating or licensing a one-of-a-kind drug creates an opportunity that even the greenest investor can understand. This is part of why the biotechnology industry is full of optimism, from both management and investors. And clinical-stage biotech stocks could present immense potential.
Where To Focus In 2019?
A majority of the biotech industry’s smaller members are in the clinical stage. In other words, they don’t have a product to sell yet, but they’re testing potential drugs in humans. Because of this, new milestones, announcements, progress, etc. can act as massive catalysts in a near term and possibly long term time frames. Even the slightest positive progress update can trigger momentum. Why do we mention this?
One of the hottest subsectors that has gotten more attention in 2019 has been digestive diseases especially things like liver disease, diabetes and myriad digestive system cancers. The obesity epidemic in the U.S. is leading to a new problem for doctors.
In fact, by 2020, a liver disease known as nonalcoholic steatohepatitis, or NASH , will be the leading cause of liver failure. That will lead to more liver transplants in the U.S., experts say.
“NASH is silent until it gets very advanced,” JMP analyst Bayko said. “Then it’s too late.”
The National Institutes of Health estimates 30%-40% of adults in the U.S. have a fatty liver. Of those, about 20% have NASH liver disease. But liver disease treatment is complicated, especially in the case of NASH. According to other reports, the global market for NASH could reach $35 billion .
Tiziana Life Sciences (TLSA) Has Created A Biotech Pipeline To Address Multi-Billion Dollar Market Opportunities
There are many companies out there working to treat liver disease and other forms of digestive tract diseases, but one company could stand to disrupt this $35 billion market. Tiziana Life Sciences (TLSA) is focusing on to develop novel treatment for liver diseases such as NASH and hepatocellular carcinoma (HCC). With multiple treatments in advanced Phase Trials, it could make sense to have this biotechnology company in focus for 2019.
Tiziana (TLSA) is supported by extensive IP and a strong pipeline of in-licensed clinical assets and has clinical development programs for Foralumab and Milciclib. Strong IP for oral and nasal administration is for the platform technology, which is applicable to all antibodies drugs for the treatment of human diseases.
As you can see, there are multiple indications that Tiziana (TLSA) pipeline treatments are looking to meet. Right now, bigger companies are taking aim at buying up assets in this space. Bristol-Myers Squibb has confirmed it is looking for additional assets to enhance its internally-developed NASH drugs.
Furthermore, other companies like Pfizer have expressed the same, “We are actively looking on the outside for opportunities… to complement our internal program,” Morris Birnbaum told Reuters in an interview. He is the chief scientific officer for internal medicine for Pfizer.
Driven by the obesity and diabetes epidemics, the disease guarantees an enormous pool of patients for decades, making it a prime target for deals for promising therapies for NASH and its consequences – advanced fibrosis and liver-destroying cirrhosis.
“We anticipate that there will be more transactions, more licensing deals from big pharma involving emerging biotechnology companies,” – Dr. Scott Friedman, dean for therapeutic discovery at Mt. Sinai Hospital in New York.
How Is Tiziana Life Sciences (TLSA) Set To Shake Up The Industry?
First off, there could be huge upside potential for its current portfolio of drug candidates. And it isn’t just for the treatment of NASH but other autoimmune diseases as well. Its Milciclib has already shown to produce clinical benefits and the drug is well tolerated.
No drug related deaths were reported in a Phase 2a clinical trial in patients with inoperable or metastatic Hepatocellular Carcinoma – a type of liver cancer. In fact, 28 out of 31 of the patients treated could be evaluated with 14 patients having completed a 6-month study. Nine of these patients continued treatment under compassionate use and 5 are still under treatment.
“We are very pleased with the clinical activity and tolerability of Milciclib in these advanced cases of HCC. It is an important milestone to move forward with further clinical development of Milciclib either as a single agent or in combination with other HCC drugs,” said Dr. Kunwar Shailubhai, CEO & CSO of Tiziana.
Exclusivity Makes This An Attractive Therapy To Stand Up To Industry Heavyweights
Tiziana (TLSA) holds an exclusive license from Nerviano Medical sciences for both method of use and composition that is protected through 2030. Pending patent applications extend the IP protection at least up to 2038. Milciclib has shown to have reduced toxicity and adverse events compared to current Standard of Care drugs like some of the leading therapies in the market today including:
- Sorafenib co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar
- Lenvatinib, developed by Eisai Co, and;
- Regorafenib, developed by Bayer
Last year, Tiziana Lifesciences presented a poster at the AASLD, a premier scientific conference for liver diseases, demonstrating that milciclib produces significant synergistic activity in combination with tyrosine kinase inhibitors (TKIs) such as sorafenib, regorafenib and lenvatinib in preclinical studies. In addition, oral treatment with milciclib is also able to overcome drug resistance towards commonly used chemotherapeutic drugs such as gemcitabine.
Because it can be combined with TKIs as well as standard chemotherapy agents, Tiziana’s treatment could be in a position to directly compete with the therapies of some of the biotech sectors biggest companies. What may be more important is that patients often become resistant or unresponsive to certain treatments.
According to Tiziana, Milciclib works through a unique mechanism with broad-spectrum action to address the complex heterogeneity in HCC patients. The drug could have the potential for long-term efficacy.
Just think about this for a moment: The global market for liver cancer drugs is estimated to reach $1.47 billion by 2022. The current standard of care drugs is not entirely satisfactory due to low response rates and severe toxicities where Tiziana (TLSA) could be positioned to capitalize.
Just The Tip Of The Iceberg
But keep in mind; Tiziana (TLSA) isn’t just focusing on liver cancer. As we discussed, the company has a pipeline of treatments aimed at liver and other diseases. The company’s Foralumab could also present new opportunities to address Crohn’s disease and indications for NASH – that “small” addressable market we were talking about before.
Tiziana’s Foralumab is the first fully human anti-CD3 mAb, which has not shown anti-drug antibody (immune reaction) in humans. Tiziana’s proprietary platform technology for oral and nasal administration of mAb’s could provide clinical benefits by mimicking the body’s natural immune modulation processes and thereby increasing patient compliance.
Foralumab has recently completed a Phase 1 trial at the Harvard Medical School in healthy volunteers to study safety, tolerability and biomarkers of neurodegenerative disease through nasal delivery. The clinical data from this trial will be publicly reported shortly. Why timing could be so important right now for those looking at Tiziana (TLSA).
The company will also be starting an additional Phase 1 trial to evaluate oral Foralumab’s safety, tolerability and biomarkers of anti-inflammation in healthy volunteers. While the oral administration of Foralumab is for treatments of Crohn’s disease and NASH, the nasal administration is for treatment of neurodegenerative diseases such as progressive multiple sclerosis (pro-MS).
Furthermore, a Phase 2 trial in Crohn’s and NASH is expected to commence next year. So, those taking a closer look at Tiziana (TLSA) right now could not only see it in the midst of big progress with its Milciclib but also during a time when Foralumab’s progress is just getting started.
“Tiziana’s proprietary technology for the oral and nasal delivery of mAb’s in general, and Foralumab specifically have strong potential indications in autoimmune diseases including Type 1 diabetes, Crohn’s disease and NASH”Kunwar Shailubhai, CEO & CSO of Tiziana
If this weren’t quite enough to make a point, third party researchers in the peer-reviewed journal Crohn’s & Colitis 360* point out the immense potential for Tiziana’s (TLSA) Foralumab. Titled, “Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis,”  the published study was conducted at some of the leading medical research institutions in the world.
This included Harvard Medical School, Massachusetts General Hospital, and the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital. According to the company, these independent findings suggest potential clinical activity and support the safety of monoclonal antibodies (mAb’s) when administered orally.
The Company is pioneering oral delivery of mAb’s for the treatment of autoimmune and inflammatory diseases that is applicable to the $100 billion market of mAb’s that are currently only available through IV delivery!
An End To Humira? Tiziana May Hold The Key To Disrupt A $21 Billion Market
Tiziana (TLSA) could have the first true platform to directly take on a drug that is doing over $20 billion is sales. Abbvie’s Humira is incredibly diverse and has become one of the biggest autoimmune blockbusters in recent biotechnology history. But one huge flaw has left the door wide open for Tiziana’s (TLSA) lead therapies to capitalize.
In an autoimmune disease, the body’s immune system falsely detects and attacks a threat within the body that does not really exist. This can lead to a number of problems and conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, and psoriasis.
Just like Tiziana’s Foralumab, Humira is a monoclonal antibody that targets symptoms related to autoimmune disorders. But here’s where the opportunity is: The only way to use Humira is intravenously via an injectable syringe or pen. Foralumab can be administered nasally or orally and this simple change in delivery method could set a stage for a strong argument supporting the potential of Tiziana’s (TLSA) platform.
Timing Is Very Important In This Case
The company already has an upcoming Phase 1 trial to evaluate oral Foralumab’s safety, tolerability and biomarkers in Crohn’s disease and NASH. While the trial is primarily a safety study, it will also evaluate biomarkers for T regulatory cells (Tregs) and anti-inflammation.
Considering the early successes that the drug has already had, there will be a very particular focus on what’s next. It will see if there are positive immune-modulatory effects on these biomarkers to ultimately show the true potential of oral treatment with Foralumab. Most importantly, if there is any indication of improvement from a nasally-taken treatment it could be a significant breakthrough for the company!
Up until today, there has never been a fully human anti-CD3 antibody. If they can demonstrate success with their data, Tiziana (TLSA) could become the pioneers of this type of treatment. The big advantage is that the delivery of CD3 antibody through IV is directly associated with toxicity. For Tiziana (TLSA), the possibility of delivery, orally or nasally, it could circumvent the risks associated with the toxicity risk of intravenous delivery methods currently in place.
If Tiziana (TLSA) can demonstrate it can deliver the same fully humanized antibodies in a non-injectable method, it could be a huge breakthrough in science and disease. The potential goes beyond “just a delivery method.”
The company also holds patents that include the fully humanized aspect of the technology (versus mouse-derived) as well as covering the delivery methods (nasal & oral) which include existing and approved monoclonal antibodies like Humira and Remicade – TWO BLOCKBUSTER DRUGS!
If Abbvie or Johnson & Johnson wanted to deliver these treatments orally or nasally, they would need to utilize Tiziana’s (TLSA) patents. Gabriele Cerrone, the company’s Chairman sums it up perfectly, “A lot of people are sitting on the side lines really curious to see if you can deliver an anti-CD3 any other way than injecting. But as soon as we have the data to show it is effective the days of being a [small cap] company are finished.”
This comes from a man who is no stranger to successfully founding biotechnology companies. Mr Cerrone co-founded Trovagene, Inc. (NASDAQ: TROV), a molecular diagnostic company and served as its Co-Chairman. He was a Director of and led the restructuring of Siga Technologies, Inc. (NASDAQ: SIGA). Mr Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007 with Inhibitex, Inc. Mr Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb.
Mr Cerrone is the Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology using microRNA technology; Chairman and Founder of Tiziana Life Sciences plc (TLSA) an oncology focused therapeutics company; Chairman and Co-Founder of Rasna Therapeutics Limited, a company focused on the development of therapeutics for leukaemias; Co-Founder of ContraVir Pharmaceuticals, Inc. (fmr: CTRV now HEPA); and founder of BioVitas Capital Ltd.
So when a man of this stature explains the sheer potential and timing of all of this, it may be prudent to start listening and watching closely.
Elite Team Of Management
Mr. Cerrone is just one very valuable piece of a much large, elite management team behind Tiziana Life Sciences (TLSA).
Dr. Napoleone Ferrara
Dr Ferrara’s research led to the development of the anti-VEGF monoclonal antibody bevacizumab (Avastin®) which was initially approved for the treatment of colorectal cancers, now one of the top ten selling global pharmaceutical products and won the 2010 Lasker Award for his work on VEGF. Dr Ferrara is Senior Deputy Director for Basic Sciences at University of California’s Moores Cancer Center in San Diego; and Distinguished Professor of Pathology at the University of California’s School of Medicine, also in San Diego.
Dr. Howard Weiner
Dr. Howard Weiner is the Director and Founder of the Partners Multiple Sclerosis (MS) Center and Co-Director of the Ann Romney Center for Neurologic Diseases at Brigham & Women’s Hospital in Boston. The Partners MS Center is the first integrated MS Center that combines clinical care, MRI imaging and immune monitoring to the MS patient as part of the 2000 patient CLIMB cohort study. He has pioneered immunotherapy in MS and has investigated immune mechanisms in nervous system diseases including MS, Alzheimer’s disease, amyotrophic lateral sclerosis, stroke and brain tumours. He has also pioneered the investigation of the mucosal immune system for the treatment of autoimmune and other diseases and the use of anti-CD3 to induce regulatory T cells for the treatment of these diseases.
Kunwar Shailubhai, Ph.D., M.B.A. serves as Chief Executive Officer and Chief Scientific Officer of Tiziana Life Sciences, and is also an Executive Director of the Company. Dr. Shailubhai invented Plecabatide, which was approved by the FDA for GI diseases in 2016. Further, his experience has lead him to top tier biotech companies holding various roles at Rasna Therapeutics, Monsanto Company, and was co-founder, EVP & CSO of Synergy Pharmaceuticals, Inc.
Clinical Stage Biotech Stocks Could Present First-In-Line Opportunity
Anyone can call a blue-chip biotech stock a success but were they there when that company was in its clinical stages? If that question were asked to most about Pfizer or Bayer today, the answer would likely be “no.”
But there are countless examples of clinical-stage companies hitting it big after reporting meaningful trial results. And it’s usually the early onlookers who may have the upper hand at capitalizing:
Deciphera Pharmaceuticals, Inc. more than doubled after reporting positive top-line results from a phase 3 clinical study from $19.95 to as high as $42.99… 115%
CorMedix, Inc. Exploded From $6.30 to $13.60 Following Positive Interim Study Results … 116%
CEL-SCI Corporation Jumps From $3.00 March 2019 To Nearly $9 Following Series Of Phase Trial Updates… 199%
Corindus Vascular Robotics, Inc. Rallies from $0.99 At the Start of 2019 to highs of $4.27 Following Agreement to Be Acquired By Siemens Healthineers Just 8 Months Later… 331%
Zynex Rallies From Just $2.60 in January to highs of $11.75…351%
And these are just a few examples of biotech stock catalysts that sent these companies soaring in 2019! While many of the drugs in development are two-to-five years from reaching the market if they get that far, betting on the feverish deal activity could give investors a chance to profit near term.
It doesn’t take a rocket scientist to see that biotech catalyst can trigger massive runs, especially in smaller companies. Many small companies developing drugs with a wide variety of approaches across the disease spectrum do not have partners, Tiziana (TLSA) included.
So with the major progress being observed on a number of pipeline therapies, Tiziana (TLSA) may be approaching critical mass as it were. The market for its drugs has become ripe with opportunities and the latest trend in the biotech sector could lead the way for a new groundswell to begin before the end of the year.
With the recent progress that the company has seen from its early trials, the fervent demand for new therapies, and the stampede of investments flooding into the market from major biotech leaders, it may be time to start looking at small-cap biotech stocks before the Main Street rush opens the floodgates.
Top 5 Reasons To Have Tiziana Life Sciences (TLSA) On You Biotech Stock List
1. Major acquisition trends from large-cap biotechs could open near term opportunity for promising drug therapies from smaller cap companies
2. Favorable trial results demonstrate considerable potential from Tiziana Life Sciences (TLSA) treatment pipeline. More near term potential could present itself leading up to Foralumab safety trials & pit it head-to-head with Humira.
3. Additional benefits of Tiziana’s (TLSA) therapies extend to other hotbed markets like Diabetes, Arthritis, and liver cancers to name a few
4. The market opportunity for NASH therapy alone concerns a $35 billion market
5. Early-stage catalysts for clinical biotech stocks have presented first-mover advantages & Tiziana Life Sciences (TLSA) has a number of major milestones that could point toward further clinical developments to come.
 Boden, E. K., Canavan, J. B., Moran, C. J., McCann, K., Dunn, W. A., Farraye, F. A., Ananthakrishnan, A. N., Yajnik, V., Gandhi, R., Nguyen, D. D., Bhan, A. K., Weiner, H. L., Korzenik, J. R., Snapper, S. B. Immunologic alterations associated with oral delivery of anti-CD3 (OKT3) monoclonal antibodies in patients with moderate-to-severe ulcerative colitis. Crohn’s & Colitis 360 (2019). 183: 240-246.
Pursuant to an agreement between Midam Ventures LLC and Tiziana Life Sciences plc (TLSA), Midam has been paid $150,000 by Tiziana Life Sciences plc (TLSA) for a period from August 22, 2019 to September 22, 2019. We may buy or sell additional shares of Tiziana Life Sciences plc (TLSA) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Tiziana Life Sciences plc (TLSA). Full Disclaimer Click Here
Stock Price Newsletter – August 23, 2019
Biotech Stocks To Watch This Quarter
With a wave of groundbreaking products in the pipeline, biotechnology could be poised to keep churning higher for the foreseeable future. But how can you get in on the ground floor of the next big wave in biotech?
Can Apple (AAPL) Stock Price Catch A Boost From AppleTV+?
Apple Inc. (AAPL Stock Report) is growingly shifting its dependence on other categories of products as iPhone sales continue the decline. The biggest bets for the company involve services and at the beginning of the year, they introduced four new services that are Apple News+, The Apple Card, Apple Arcade and the Apple TV+.
2 Chinese Stocks Making Bullish Moves
The trade war with the United States and an economic slowdown for the first time in three decades has cratered the markets in China. China-based stocks have generally underperformed over the course of the past year. But even during such a slowdown, some stock prices have been showing bullish tendencies. Here is a look at two such China-based companies that have seen stock prices climb.
Search Stock Price (StockPrice.com)
Sponsored Content2 months ago
Special Delivery! On-Demand Tech Companies Hit Billion-Dollar Valuations; Here’s How Investors Can Capitalize In The Market
Featured5 months ago
Multi-Trillion Dollar Industry Providing Massive Opportunity in 2019 & Beyond
Cannabis4 months ago
Two Massive Growth Industries, One Choice for Investors
Biotechnology3 months ago
Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks
Featured2 months ago
This New Technology Could Transform A Multi-Billion-Dollar Industry!
Cannabis3 months ago
A New Cannabis Trend That The Market Should Take Immediate Notice Of Is Here!
Biotechnology1 month ago
PharmaCyte Biotech (PMCB) and UTS Creating Advanced Version of Melligen Cells to Treat Diabetes
Biotechnology2 months ago
The Future Of Drug Delivery Has Biotech Investors Focusing On One Small Company